Allogeneic BMT is potentially curative for @entity1 with @entity3052 ( @entity3052 ) in first remission. However, many @entity1 relapse after transplantation. Various immunotherapeutic options have been attempted with variable success in preventing relapse. Early identification of @entity1 at high risk for relapse could allow prompt intervention. We examined the effect of slow lymphocyte recovery after sibling-matched allogeneic BMT on the risk of relapse in @entity1 with @entity3052 . We also examined the effect of @entity229 -containing GVHD prophylaxis on the rate of lymphocyte recovery. @entity1 with @entity6660 ( @entity6660 ) <150 x 10(6)/l by day +30 had a 3.5-fold higher risk of relapse (P = 0.0088) and a lower overall survival (P = 0.0079) than @entity1 with a higher @entity6660 . We did not find correlation between lymphocyte count determined earlier in the post-transplantation course (day +21) and the risk of relapse. @entity1 receiving @entity229 had a significantly lower @entity6660 at day +30 than those who did not receive @entity229 (289 vs 549 x 10(6)/l, P = 0.002). We conclude that a slow lymphocyte recovery after allogeneic BMT for @entity3052 is strongly predictive of subsequent relapse and that the type of GVHD prophylaxis should be considered when analyzing lymphocyte recovery.

Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone'] @entity6660 :: ('MESH:D009845', 'Disease') :: ['ALC', 'absolute lymphocyte count'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myelogenous leukemia', 'AML']
@entity3052 :: (MESH:D015470,Disease) :: ['acute myelogenous leukemia']
